Cleerly Raises $106 Million in Funding Led by Insight Partners to Revolutionize Heart Disease Care
DENVER, Dec. 4, 2024 /PRNewswire/ -- Today Cleerly, a leader in advanced cardiovascular imaging, announced the successful closure of its Series...
Heart Attack
Cepham Increases Commitment to Men’s Health With Emphasis on Wellbeing and Plant-Based Ayurvedic Care
SOMERSET, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cepham is increasing its commitment to men’s health during the holiday season...
Avricore Health Corporate Update: Effective Plan, Resources Result in Success
VANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its...
AHA 2024: Powerful Medical Makes History as First to Win Both Best Science Startup and Overall Winner Awards
CHICAGO, Nov. 27, 2024 /PRNewswire/ -- Powerful Medical became the first company to win both the Best Science Startup and...
Cleerly Makes Debut at RSNA 2024, Showcasing AI-Enabled Innovations in Cardiovascular Imaging
Join Cleerly Leadership for Live Demonstrations on Advanced Imaging Solutions for Personalized Heart Disease Care DENVER, Nov. 26, 2024 /PRNewswire/...
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions...
Avive Solutions Partners with Academy Safe: Advancing Safety Standards for Martial Arts Studios Across the U.S.
SAN FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Avive Solutions is proud to announce its partnership with Academy Safe, a non-profit organization...
SEEHER, ABBOTT, AND CVS RELEASE FIRST-EVER HEALTH AND WELLNESS REPORT TO COMBAT HOW WOMEN HAVE BEEN DEPRIORITIZED AND UNDERREPRESENTED IN HEALTHCARE MARKETING
Women are the key decision makers in 80% of all healthcare choices, yet many brands fail to accurately portray them...
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy...
FDA Grants De Novo Authorization to OMRON Healthcare for New Blood Pressure Monitors with AI-Powered AFib Detection Feature
Advancing its Going for Zero mission, OMRON innovation makes AFib screening an integral part of the brand's routine home blood...
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to...
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding...
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present...
Cumberland County and The Peyton Walker Foundation Celebrate the First Life Saved in the U.S. Using Avive Solutions’ New AED Technology
SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- On July 16, 2024, a life-saving event unfolded when a trained citizen volunteer...
Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024
Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans...
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing...
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual...
Dynocardia’s Direct Continuous Blood Pressure Monitoring Technology Receives Grant from NIH’s Commercialization Readiness Pilot Program
The grant, which is awarded to companies developing significantly impactful technologies with the potential to change clinical practice, will support...
New Study Finds Twin Health Treats Hypertension in Patients with Type 2 Diabetes
The digital twin AI platform helps patients safely eliminate blood pressure medications and sustain normal blood pressure MOUNTAIN VIEW, Calif.,...
Lexaria Updates Current GLP-1 Market
KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a...